Tumor endothelial marker 1 (Tem1; endosialin) is the prototypical member of a family of genes expressed in the stroma of tumors. To assess the functional role of Tem1, we disrupted the Tem1 gene in mice by targeted homologous recombination. Tem1 ؊/؊ mice were healthy, their wound healing was normal, and tumors grew normally when implanted in s.c. sites. However, there was a striking reduction in tumor growth, invasiveness, and metastasis after transplantation of tumors to abdominal sites in mice without functional Tem1 genes. These data indicate that the stroma can control tumor aggressiveness and that this control varies with anatomic site. Therefore, they have significant implications for the mechanisms underlying tumor invasiveness and for models that evaluate this process.
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endosialin ͉ metastasis ͉ stroma ͉ tumor invasiveness ͉ angiogenesis T umor angiogenesis is required for the growth of human tumors to clinically relevant sizes (1) (2) (3) (4) . Global analysis of altered gene expression patterns in endothelial cells from human colorectal cancer tissues identified a series of genes termed tumor endothelial markers (TEMs) (5) . These genes were found to be overexpressed in the endothelium of both human and animal tumors (5) (6) (7) . TEM1 is the prototype of this class, with its mRNA exhibiting the highest differential expression between normal and human tumor endothelium. Interestingly, after its discovery as a TEM, TEM1 was found to encode endosialin, the antigen recognized by a monoclonal antibody that had been developed nearly a decade earlier and shown to specifically react with human tumor endothelium and fibroblast-like cells within the tumor stroma (8, 9) . Endosialin is a 165-kDa single-pass transmembrane glycoprotein that has been classified as a C type lectin-like membrane receptor. It has multiple extracellular domains consisting of three EGF-like domains, a sushi-like domain, and a C lectin-like domain (6, 9) .
In addition to the importance of TEM gene products as potential therapeutic targets (10, 11) , the study of their functional role(s) may provide new insights into angiogenesis. Toward this goal, we generated a mouse model with a targeted null mutation in the Tem1 gene. We demonstrate that Tem1 is not required for angiogenesis during fetal development, postnatal growth, or wound healing. However, optimal growth, invasion, and metastasis of tumors implanted in abdominal sites of adult mice were found to critically depend on Tem1 expression. These data demonstrate that Tem1 plays a critical role in determining tumor behavior in clinically relevant anatomical sites.
Results

Generation and Characterization of Tem1 Knockout (KO) Mice.
A targeting vector was designed to knock out the Tem1 gene by homologous recombination in mouse ES cells (Fig. 1A) . PCR was used to distinguish homozygous (KO), heterozygous (HET), and WT mouse genotypes (Fig. 1B) . Tem1 has been reported to be expressed during embryonic development but at very low levels in adults (6) . Using RT-PCR, we detected Tem1 expression in embryonic liver, skin, and colon late in gestation (embryonic day 15.5) of WT but not KO mice (Fig. 1C) . Null mice of both sexes were phenotypically normal, and crossing HET male and female mice resulted in WT, HET, and null offspring at the expected Mendelian ratios and litter sizes ( Fig. 2A ). There were no differences in growth rates between WT and KO mice (Fig.  2B) . Additionally, no abnormalities were apparent in any organ system after complete histopathological analysis of fetal, newborn, and adult mouse tissues. These experiments demonstrated that Tem1 disruption did not cause any lethal embryonic defects or interfere with development or fertility. significant differences in the rate of wound closure between KO and WT mice (Fig. 3A) . Histopathological examination of the wound sites also revealed no morphological differences during wound healing in these mice. To examine the process of angiogenesis in wounds, the vasculature was stained for PECAM-1 or with rabbit anti-human von Willebrand factor (Factor VIII). Stained vessels were quantified in histological sections made from the wound site at the time of closure (14 days) . No morphological differences between KO and WT mice were apparent at the wound sites. In addition, there were no differences in the number or size of vessels formed at the site of the wounds (Fig. 3B) .
We next compared the growth of s.c. tumors in KO and WT mice. There were no differences in the growth rate of the Lewis lung carcinoma (LLC) tumor cell line (Fig. 3C) or the S180 sarcoma cell line (data not shown) after s.c. injection into KO and WT mice. We conclude that skin wound healing and the growth of s.c. tumors does not depend on Tem1 expression.
Abdominal Orthotopic Xenografts in Immunodeficient Mice. Because the TEM1 transcript was first identified by virtue of its overexpression in the endothelium of colorectal tumors, we compared the growth of HCT116 human colorectal cancer cells as orthotopic xenografts in an immunodeficient, nude mouse background. Tumor fragments derived from the HCT116 cell line were surgically attached to the serosal surface of the large intestines of KO and WT nude mice. Over a 19-day period of tumor growth, KO mice survival was 89% compared to 11% for WT mice (Fig. 4A ). In addition, WT mice had a much higher incidence of peritoneal carcinomatosis (89% vs. 33%) and liver metastases (33% vs. 0) than KO mice (Fig. 4B) . Accordingly, total tumor volume was significantly larger in WT compared to KO animals (P Ͻ 0.018).
Tumor Growth at Abdominal Sites in Immunocompetent Mice. The growth of implanted tumors at abdominal sites was compared in immunocompetent KO and WT mice by using the LLC cell line. In the first set of experiments, tumor fragments were surgically implanted into the livers of KO and WT mice as described in Methods. Three weeks after surgery, the tumors in WT mice had grown to an average volume that was more than twice that of tumors implanted into the livers of KO mice ( Fig. 5A , P Ͻ 0.041). In a second set of experiments, tumor fragments were surgically implanted onto the serosal surface of the large intestine. The tumors in WT mice grew to more than four times the average tumor volume compared to similarly implanted tumors in KO mice ( Fig. 5B , P Ͻ 0.0002). The pattern of growth was strikingly different in WT vs. KO mice. The tumors in WT mice grew spherically around the entire colon, encircling it within a large tumor mass (Fig. 5 C and D) . In contrast, the tumors in KO mice grew only laterally, generating flattened lesions along the serosal surface ( Fig. 5 C and D) . Histologically, tumors from WT mice not only expanded spherically but also extensively invaded the full thickness of the intestine, including the epithelial layer lining the intestinal lumen (Fig. 5E) . Growth of the tumors in KO mice abruptly ceased when cells reached the lamina propria, completely failing to invade the inner layers of the intestine (Fig. 5E ).
Vascularization of Implanted Tumors. As expected, Tem1 expression was detected in the tumors in WT animals beginning at 2 weeks after transplantation in WT mice but could not be detected in KO mice (Fig. 6A) . In situ hybridization performed at 3 weeks of tumor growth revealed that VE-cadherin-positive blood vessels were present in the tumor stroma of both WT and KO mice (Fig. 6B) . In contrast, Tem1 expression was detected in cells lining vessels and in fibroblast-like cells in the stroma of tumors grown in WT mice but in neither cell type of Tem1 KO mice (Fig. 6B) .
We quantified the number of vessels of various sizes in sections of tumors that had been implanted on the serosal surface of colons in immunocompetent mice. For this purpose, formalinfixed sections were stained by immunohistochemistry for CD31 antigen (PECAM-1), a marker of vascular endothelium (Fig.  6C ). Vessels of 50-100 m diameter and those of Ͼ100 m diameter were more numerous in tumors from WT than in those from KO mice, although this difference was not statistically significant (Fig. 6D) . However, there was a statistically significant increase in the number of smaller vessels (Ͻ50 m diameter) in tumors from KO mice compared to those from WT mice (Fig. 6D ). There was no qualitative or quantitative differences in tumors grown in KO or WT mice when assessed by immunohistochemistry with antibodies to alpha-smooth muscle actin (data not shown). This marker for pericyte coverage of vessels increases with vessel maturation.
Discussion
The results reported above demonstrate that Tem1 plays an important functional role in experimental tumor progression. KO of Tem1 dramatically changed tumor growth patterns, altered vascularization, decreased bulk growth, prevented local invasion, and reduced metastasis. Interestingly, these alterations in tumor growth were not accompanied by any apparent abnormalities during early development or in wound healing. They suggest that tumors are more than unhealed wounds and that specific host-associated factors like Tem1 play a very specific role in tumor stroma formation (12) . The fact that dramatic effects were observed in abdominal but not s.c. tumors demonstrates that the associated processes were organ-site specific. It may be relevant that normal angiogenic factors can also be expressed in an organ site-specific fashion (13) (14) (15) (16) (17) (18) . One of the most important implications of the work described here is that conventional animal models for studying tumorigenesis, employing s.c. inoculation of tumor cells, may not be optimal for assessing the physiologic parameters that govern tumor cell growth and invasion in their natural environment (19, 20) . Specific factors from stromal cells that influence tumor progression, invasion, and metastasis are only beginning to come to light (21) (22) (23) (24) (25) (26) . Recent examples include the CXCL14 and CXCL12 chemokines that are overexpressed in tumor myoepithelial cells and myofibroblasts, respectively, and bind to receptors on epithelial cells and enhance their proliferation, migration, and invasion (27, 28) . TEM1 expression is presumably confined to the cell surface and, thereby, would be expected to mediate its effects through direct cell to cell interactions rather than via a paracrine manner.
Our results are consistent with previous studies showing that Tem1 is expressed predominantly on cells lining blood vessels but could also be detected on fibroblast-like stromal cells (6, 8, 29) . The in situ hybridization techniques we used in mice cannot discriminate between endothelial cells and pericytes. Similarly, we cannot distinguish whether the effects of Tem1 disruption are due to the absence of Tem1 expression in blood vessels vs. their absence in fibroblast-like stromal cells. The interesting possibility exists, therefore, that the effects on tumors are primarily due to the absence of Tem1 in the fibroblastic stroma. According to this hypothesis, the increased number of small blood vessels that are observed in the stroma of tumors in Tem1 KO mice represent the response to an abnormal microenvironment (21) (22) (23) (24) (25) (26) . We speculate that interaction between tumor cells and endosialin normally induces the expression of other proteins in the tumor cells or stroma that facilitate tumor invasion and growth. In the absence of Tem1, a different gene expression program is called into play, one that is not conducive to invasion but is angiogenic. In an alternate hypothesis, the effects of TEM1 on vessels and tumor growth may be exclusively dependent on TEM1 expression in vessels. According to this model, TEM1 would be required for the efficient maturation of vessels within tumors. In Tem1 KO mice, vessels would fail to mature efficiently, leading to decreased numbers of medium and large vessels and a compensatory increase in small vessels. This abnormal angiogenic response could dampen tumor growth and invasion. Regard- less of which model holds true, the data indicate that the stroma can control tumor aggressiveness, and, importantly, that this control can vary with anatomic site.
Our results raise several questions that can be addressed in future studies. Cell-specific KO of the Tem1 gene should be able to determine whether the effects of Tem1 on tumor growth are due to its expression in fibroblastic stromal cells rather than vascular cells. Identification of the receptor for Tem1, and its intracytoplasmic signaling pathways, will obviously be crucial to further understanding the mechanisms through which Tem1 affects tumor invasiveness.
Methods
Targeting Construct and Generation of Tem1 Null Mice. Genomic DNA clones were isolated from a bacteriophage library generated from 129SvEv mice (Taconic Farms). A targeting vector (pKO Scrambler 907, Stratagene) was constructed in which the neo (reverse orientation) and diphtheria toxin genes were included for positive and negative selection, respectively. A 5.8-kb 5Ј genomic homology arm and a 3.4-kb 3Ј genomic homology arm were used to target the single exon Tem1 gene. Electroporation of 129SvEv ES cells, selection of colonies, and microinjection into 129SvEv blastocysts to generate chimeric mice was performed by using conventional methods (inGenious Targeting Laboratory, Stony Brook, NY). Appropriate targeting by 5Ј and 3Ј homology arms was confirmed by PCR. Chimeric mice were mated to C57Bl6 to select for germline transmission and generate heterozygotes. Mouse colonies were generated by using a mating scheme devoid of parent-offspring and sibling matings to maintain a mixed genetic background. All experiments except those involving xenografts were carried out on mice of this mixed B6͞129 background. For xenograft experiments, B6͞129 mice were crossed with outbred nude mice (Charles River Laboratories) to generate colonies of null and WT Tem1 nude mice. All animal experimental procedures were approved by the Institutional Animal Care and Use Committee at The Johns Hopkins University.
Genotyping of Tem1 Mutant Mice by Genomic PCR. Genotyping was carried out by PCR of DNA isolated from tail clippings (GenElute, Sigma). The primers used were as follows: 5Ј-AGCGCATGCTCCAGACTGC-3Ј and 5Ј-CGTCTGGTTT-GAGTTAGGGG-3Ј to detect the mutant allele and 5Ј-TCTACCCTCAGCTACCCCC-3Ј and 5Ј-GCTTTGGTGGTC-GATATGTG-3Ј to detect the WT allele.
Expression of Tem1 by RT-PCR. Skin, liver, and colon from embryonic day 15.5 fetuses from WT mice and KO mice were used to assess expression of Tem1 mRNA during development. Total RNA was extracted by TRIzol (Invitrogen). Total RNA from each sample was denaturated at 68°C for 5 min, reverse transcribed into cDNA (Superscript First, Invitrogen), and then amplified by PCR. The forward and reverse primers for Tem1 were 5Ј-TATCCAGACCTGCCTTTTGG-3Ј and 5Ј-GGTATC-CCCAGGATCAAGGT-3Ј, and for GAPDH, were 5Ј-CG-GAGTCA ACGGAT T TGGTCGTAT-3Ј and 5Ј-AGCCT-TCTCCATGGTGGTGAAGAC-3Ј, respectively. PCR products were evaluated by agarose gel electrophoresis and at least three RNA preparations from different animals were used to confirm all results. A similar RT-PCR assay was used to evaluate Tem1 expression over time in LLC tumors transplanted to the colons of WT and KO mice.
Body Growth and Wound Healing. To determine the growth rate, mice were weighed twice a week from 5 days to 6 weeks of age in animals of both sexes. To assess wound healing, 7-week-old female null and WT female mice were anesthetized and the left flank was shaved and scrubbed. A wound was created in the flank with a 6.0-mm diameter uni-punch disposable biopsy instrument (Premier, Plymouth Meeting, PA). Wound diameters were measured with an electronic digital caliper (Fisher Scientific) every other day for 14 days in three mice of each genotype. At 2, 6, 10, and 14 days, mice were euthanized and tissue collected and fixed in 10% buffered formalin for histological assessment and blood vessel counting. Tumor Fragment Implantation. Tumor fragments were prepared via s.c. injection of 1 ϫ 10 5 LLC cells in the flank of 1-month-old WT mice. After 20 days, the mice were euthanized and the tumors were removed and placed in ice-cold PBS. Six-to 7-week-old Tem1 null and WT B6͞129 female mice were used as recipients. The mice were anesthetized with isoflurane, and the abdomen was scrubbed for surgery. A small incision was made parallel to the linea alba, and the cecum was exteriorized. A single fragment of tumor of Ϸ1 mm 3 in size was implanted on the top of the serosal surface. A surgical suture was used to attach the tumor to the serosal wall without penetrating the inner layers of the intestine. The organ was returned to the abdominal cavity, and the abdominal wall was closed. For transplantation to hepatic sites, an incision was made in the ventral left upper abdominal quadrant. The left lobe of the liver was carefully exposed, and a blunt needle was used to puncture the liver capsule. A single fragment of tumor of Ϸ0.5 mm 3 in size was then placed in the hole made by the needle. After hemostasis, the abdomen and skin were closed. Both intestinal and intrahepatic transplantation surgeries were repeated twice by using six animals each time for each group. Complete necropsies and histological examination were performed after 21 days in mice with either type of transplantation. Abdominal tumor volumes were measured by using the formula (͞6) ϫ length ϫ width ϫ height. Along with the tumors, the colon, liver, lung, and other organs were placed in buffered 10% formalin, processed, sectioned, and either stained for hematoxylin͞eosin or used for in situ hybridization or immunohistochemistry.
Histology, Immunohistochemistry, Vessel Quantification, and in Situ Hybridization. To quantify vascularization, 5-m-thick sections of transplanted tumor or tissue from the experimental skin wounds were deparaffinized in xylene and rehydrated through graded alcohols. Five mice were used for each group. Endogenous hydrogen peroxide was quenched with peroxidase for 10 min. Slides were then incubated with blocking solution [10% bovine serum (Vector Laboratories) in PBS] for 60 min at room temperature to saturate nonspecific protein-binding sites. The slides were incubated with primary antibody [goat anti-PECAM-1 (sc-1506; Santa Cruz Biotechnology) at 1:50; rabbit anti-human von Willebrand factor (vWF; AB7356; Chemicon) at 10 g͞ml in PBS; or mouse anti-smooth muscle actin (A2547; Sigma)] for 1 h at room temperature. After three washes with 0.1% Tween 20 in PBS, sections were incubated for 30 min with appropriate secondary antibody diluted in blocking solution. Slides were developed with ABC reagent and diaminobenzidine. Photographs of histological sections were taken with a digital camera (Nikon Dx1200). Number and diameter of all blood vessels in the tumor or wound bed area were determined in 10 high power fields (ϫ400). In situ hybridization was performed on paraffin sections by using a modification of a protocol described in ref. 5 . A detailed protocol is available upon request.
